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MicroRNAs regulate the expression of many genes and subsequently control various cellular processes,
such as the immune response to viral infections mediated by type I interferon (IFN). In this study,
the expression pattern of two interferon-related microRNAs, miR-146a and miR-155, was examined in
healthy and HCV-genotype-4-infected peripheral blood mononuclear cells (PBMCs) using qRT-PCR. In
contrast to other viral infections, the expressionpatternwas similar in bothhealthy and infectedPBMCs.
This could be attributed to attenuation of IFN pathway by HCV, which was assessed by investigating
the expression of MxA, an interferon-stimulated gene, that showed lower expression in HCV-infected
PBMCs. To determine the site of interference of HCV in the IFN pathway, expression of both microRNAs
was examined following stimulation of PBMCs with IFN-α2a, an activator of the JAK/STAT pathway
as well as with imiquimod, a toll-like receptor-7 (TLR-7) agonist that promotes interferon release. IFN
stimulation induced the expression of miR-146a and miR-155 in HCV-infected and healthy PBMCs.
Stimulation with imiquimod led to a down-regulation of both microRNAs in infected PBMCs, while it
increased their expression in healthy PBMCs, indicating that HCV might interfere with miR-146a and
miR-155expressionat sitesupstreamof interferonrelease, speciﬁcally in theTLR-7pathway. Thepattern
of expression of both miR-146a and miR-155 was very similar with a strong positive correlation, but
showednocorrelation to thepatients’ clinical orhistopathological parameters or response to treatment.
In conclusion, HCV infection might repress the induction of miR-146a and miR-155 by interfering with
TLR-7 signaling.
c© 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
VariousmicroRNAs are now being investigated in hepatitis C virus
infection with the most popular one being miR-122 for its reported
speciﬁcity to liver tissue [1]. miR-122 was found to interact with HCV
RNA enhancing its replication [2], despite that, it showed aberrant ex-
pression in HCV infected liver tissues [3]. miR-122 was also reported
to be a possible predictor of response to interferon treatment, where
non-responders (NRs) showed lower pre-treatment miR-122 expres-
sion compared to sustained virologic responders (SVRs) [4]. Several
other microRNAs have also been identiﬁed to be possible predictors
of response in HCV infection, such as miR-27b, miR-422b and miR-
378, which showed lower expression in NRs compared to completeAbbreviations: miR, microRNA; PBMCs, peripheral blood mononuclear cells; IFN,
interferon; TLR, toll-like receptor
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http://dx.doi.org/10.1016/j.fob.2012.07.005early virologic responders (cEVRs), while the expression of miR-34b,
miR-145, miR-143, miR-652 and miR-18a was signiﬁcantly higher in
NRs than in SVRs [5]. The effect of IFN-β, a component of the in-
nate antiviral immune response, on microRNA expression in Huh7
cells was previously investigated, where the expression of eight mi-
croRNAs with sequence complementarity to the HCV genome of the
six genotypes was induced upon treatment with IFN-β. These mi-
croRNAs are miR-1, miR-30, miR-128, miR-196, miR-296, miR-351,
miR-431 and miR-448. Five of them (miR-196, miR-296, miR-351,
miR-431 and miR-448) showed substantial attenuation of viral repli-
cation after being induced by IFN [6]. miR-146a and miR-155 are also
associated with the IFN pathway, but they were not among those
investigated in this study. However, they were examined in a non-
HCV infection in other studies, where murine macrophages infected
with Vesicular Stomatitis Virus (VSV) showed an up-regulation of
both microRNAs [7, 8]. The up-regulation of miR-146a and miR-155
in response to VSV infection occurred via a RIG-I/NF-κB dependent
pathway [7, 8]. Expression of miR-146a and miR-155 is also induced
in response to interferon and TLR-7 agonist, imiquimod, in various. Open access under CC BY-NC-ND license.
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ncell types [9, 10]. miR-146a suppresses the production of type I IFNs
by targeting and inhibiting interleukin 1 receptor associated kinase
(IRAK) 1 and 2 and tumor necrosis factor (TNF)-associated factor 6
(TRAF6) [11], which are adaptor molecules recruited upon activation
of TLRs [12]. Moreover, it suppresses signal transducer and activator
of transcription 1 (STAT1), which is a crucial element in the JAK/STAT
pathway; thus, it acts as a negative feedback regulator of IFN signal-
ing pathways [9]. miR-155 targets suppressor of cytokine signaling
protein 1 (SOCS1), an inhibitor of the JAK/STAT pathway, leading to
enhanced activation of type I IFN signaling, hence potentiating the an-
tiviral effects of IFN [8],which indicates thatmiR-155 acts as apositive
feedback regulator of the innate immune system (Fig. 1). This reveals
the paradoxical association betweenmiR-155 andmiR-146a and host
immune responses. Besides VSV, other viral infections also induced
the expression of miR-155 and miR-146a in different cell types. In-
fection of primary human B-cells with Epstein–Barr virus (EBV) led to
an up-regulation of miR-155 [13], as for miR-146a, its expressionwas
induced in response to infection of human primary neural cells with
herpes simplex virus type 1 (HSV-1) [14]. Most of the studies that
investigated the role of microRNAs in HCV infection focused mainly
on the expression and role of microRNAs in liver tissues or hepato-
cellular carcinoma cell lines. However, it has been reported that HCV
infects peripheral blood mononuclear cells (PBMCs) and replicates
within them making these cells act as a reservoir for the virus [15].
Thismakes PBMCs an important target for investigation in HCV infec-
tion. Taking the advantage that limited data are available about the
expression of miR-146a and miR-155 especially in genotype 4 HCV
infections,which is themajor genotype in Egypt [16], our study aimed
at examining the expression proﬁle of miR-146a and miR-155 in the
PBMCs of HCV genotype 4 infected patients compared to healthy con-
trols. We were also interested in elucidating the effect of the TLR-7
agonist, imiquimod, which induces endogenous interferon release, as
well as the impact of exogenously added IFN-α2a on the expression
of miR-146a and miR-155.
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e2. Results
Fig. 2. Expression pattern of miR-146a and miR-155 in HCV infected and healthy
PBMCs. miR-146a and miR-155 expression was quantiﬁed in pooled and individual
PBMCs of HCV infected patients and healthy controls using qRT-PCR. Expression of
miR-146a (A) and miR-155 (B) did not differ between patients and controls, neither in
pooled nor in individual PBMCs. Results are expressed as mean of relative quantitation
(RQ = 2−ΔΔCT) ± standard error of the mean (SEM).2.1. Expression pattern of miR-146a and miR-155 in HCV infected and
healthy PBMCs
Pools of HCV infected and healthy PBMCs were prepared and cul-
tured in 24-well plates. The expression of miR-146a and miR-155 in
the pooled PBMCs was examined using qRT-PCR. miR-146a showed
similar expression in patients (1.864 ± 0.3426) and healthy controls
(1.238 ± 0.1675) (P = 0.5714) (Fig. 2A). The same was observed for
miR-155, where no difference in its expression was found in patients
(1.379 ± 0.195) compared to healthy controls (1.040 ± 0.1106) (P
= 0.2295) (Fig. 2B). In order to exclude any bias that can occur from
pooling of the PBMCs, expression pattern of miR-146a and miR-155
was investigated and compared between the PBMCs of 20 individ-
ual patients and 10 healthy controls without pooling. As with pooled
PBMCs no difference in the expression of miR-146a was observed in
HCV infected patients (1.568 ± 0.3651) when compared to healthy
controls (1.481 ± 0.3232) (P = 0.7414) (Fig. 2A). The same results
were obtained with miR-155, where patients (2.096 ± 0.3734) and
controls (1.349 ± 0.2926) (P = 0.2619) showed similar expression
pattern (Fig. 2B).
2.2. Viral genotype and correlation between microRNA expression and
clinical parameters of patients
Genotyping revealed that all 20 patients were infected with HCV
genotype 4. The clinical data of the patients were collected (Table 1)
and analyzed for thepresence of any correlationbetween thepatients’
age, liver enzymes, ﬁbrotic stage or viral load and the expression of
miR-146a andmiR-155. MicroRNA expression showed no correlationig. 1. Host immune response to viral infection (Interferon Signaling Pathways). HCV
NA is recognized by the RNA-helicase, retinoic acid inducible gene I (RIG-I). This inter-
tion recruits IPS-1 activating a signaling cascade with a ﬁnal activation of interferon
gulatory factor 3 and 7 (IRF3 & IRF7). IRF 3 & 7 induce IFN-α production [25]. Viral
NA can also be sensed by toll-like receptor 7 (TLR-7), which recruits TRAF6, IRAK1 and
AK4, subsequently activating IRF-7 and inducing IFN-α production [12]. Released IFN
inds to its receptor, interferon-α-receptor (IFNAR), leading to phosphorylation and
tivation of janus kinase 1 (JAK1) and tyrosine kinase 2 (Tyk2). Both kinases activate
AT 1 & 2, which form a complex with IRF9 and induce the expression of the ISG, MxA
6]. The JAK/STAT pathway is regulated by SOCS1, which inhibits STAT1 activation
7]. RIG-I and TLR-7 pathways as well as IFN induce the expression of miR-146a and
iR-155 [7–9]. MiR-146a targets and inhibits IRAK1, TRAF6 and STAT1, suppressing
terferon release and the JAK/STAT pathway [9, 11], while miR-155 inhibits SOCS1,
hancing the JAK/STAT pathway [8].
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Table 1
Patients’ clinical data.
Patients Age Gender Liver enzymes (IU/L) Fibrotic Stage
Viral Load
(IU/ml) Genotype
Response to
therapy (R or NR)*
ALT* (9–40
IU/L)
AST* (10–35
IU/L)
P1 46 F 88 30 F4 3.64 × 103 4 NR
P2 42 M 60 38 F1 9.80 × 103 4 R
P3 25 M 36 31 F2 3.913 × 105 4 R
P4 45 F 53 60 F3 – F4 1.308 × 106 4 NR
P5 20 M 19 29 F0 2.47 × 104 4 n/a
P6 50 F 88 83 F0 7.10 × 103 4 n/a
P7 37 F 33 24 F1 2.00 × 105 4 R
P8 37 M 61 73 F4 7.10 × 104 4 R
P9 29 M 62 73 F2 6.48 × 105 4 R
P10 34 M 17 21 F1 3.06 × 106 4 R
P11 46 F 42 26 F1 1.14 × 106 4 R
P12 45 M 149 73 F3 5.47 × 106 4 NR
P13 33 F 126 158 F3 1.99 × 105 4 R
P14 33 F 28 26 F2 3.42 × 104 4 NR
P15 45 F 59 60 F3 2.62 × 104 4 R
P16 59 M 152 116 F4 4.28 × 103 4 n/a
P17 44 M 80 61 F3 3.54 × 104 4 R
P18 55 F 45 54 F3 2.83 × 106 4 R
P19 48 M 45 68 F1 1.60 × 107 4 R
P20 39 M 57 73 F2 6.48 × 105 4 NR
∗ Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; NR = non-responder; R = responder; n/a = response not available since patient dropped out
of therapy due to non-compliance.
Table 2
Correlation between microRNA expression proﬁles and patients’ clinical parameters. The table represents the correlation between miR-146a and miR-155 and the clinical and
histopathological parameters of the HCV infected patients (n = 20). r Value represents the Spearman’s rank correlation coefﬁcient; P < 0.05 indicates statistical signiﬁcance.
miR-146a miR-155
Age r = 0.2473 r = 0.1463
P = 0.2932 P = 0.5384
ALT r = −0.0775 r = 0.0481
P = 0.7454 P = 0.8402
AST r = 0.0506 r = 0.0710
P = 0.8322 P = 0.7661
Fibrotic stage r = 0.2271 r = 0.3028
P = 0.3356 P = 0.1944
Viral load r = 0.0541 r = −0.0323
P = 0.8206 P = 0.8923
to the different clinical, biochemical and histopathological parame-
ters (Table 2). Moreover, the baseline expression of miR-146a and
miR-155 before treatment did not correlate to the response of the
patients to the standard interferon/ribavirin therapy.
2.3. Expression pattern of MxA in PBMCs of HCV infected patients
compared to healthy controls
Baseline expression of orthomyxovirus resistance gene (MxA), an
interferon stimulated gene (ISG), was measured in pooled PBMCs
of HCV infected patients and compared to its expression in healthy
controls to assess the activity of the interferon pathway in these pa-
tients. MxA expressionwas lower in HCV infected patients (0.6740 ±
0.1110) compared tohealthy controls (1.000 ± 0.02100) (P=0.0286*)
(Fig. 3A).
2.4. Dose–response curve of interferon-α2a
A dose–response experiment was performed to determine the
dose of IFN that would induce miR-155 the most, which would be
used in the following experiments. Healthy PBMCs were stimulated
with four different IFN doses, 1500 IU/ml, 3000 IU/ml, 6000 IU/ml
and 10 000 IU/ml for 6 h, followed by quantiﬁcation of miR-155.
Surprisingly the lowest IFN dose, 1500 IU/ml, showed the highest in-
duction of miR-155 with a mean fold increase of 2.5 (P = 0.0061**).
3000 IU/ml and 6000 IU/ml of IFN showed no change in the expres-
sion of miR-155. miR-155 exhibited a mean fold increase of 2.15 (P
= 0.0061**) after stimulation with 10 000 IU/ml (Fig. 4A). According
to this curve, 1500 IU/ml of IFN showed highest induction of miR-
155 followed by 10 000 IU/ml, hence these were the doses used to
conduct the following experiments.
2.5. Effect of interferon-α2a on the expression of miR-146a, miR-155
and MxA in HCV infected and healthy PBMCs
Stimulation of pooled PBMCs with 1500 IU/ml of IFN-α2a led to a
signiﬁcant up-regulation of both miR-146a and miR-155 in patients
with amean fold increase of 3.24 (P= 0.0357*) and 2.31 (P= 0.007**),
respectively, as well as in healthy controls with a mean fold increase
of 1.74 (P < 0.0001***) and 2.51 (P < 0.0061**), respectively, when
compared to their corresponding untreated cells. Stimulation of HCV
infected PBMCs with the higher IFN-α2a dose (10 000 IU/ml) led to
a signiﬁcant down-regulation of miR-146a and miR-155 with a mean
fold decrease of −2.55 (P = 0.007**) and −2.04 (P = 0.0266*), respec-
tively, compared to the corresponding untreated PBMCs. However,
in healthy controls no signiﬁcant difference was observed in the ex-
pression ofmiR-146a upon treatment with the higher IFN dose, while
miR-155 expression was increased with a mean fold change of 2.15
(P = 0.0061**) (Fig. 5A and B). The same experiment was repeated on
PBMCs of 6 individual patients to validate that the observed effects
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Fig. 3. Effect of interferon-α2a and imiquimod on the expression of MxA in HCV
infected and healthy PBMCs. HCV infected and healthy PBMCs were cultured in a 24-
well plate and were either left untreated or stimulated with 1500 IU/ml, 10 000 IU/ml
of IFN-α2a for 6 h or with 1 μg/ml of imiquimod for 24 h, followed by quantiﬁcation
of MxA using qRT-PCR. (A) No difference inMxA expression was observed in untreated
PBMCs of HCV infected patients compared to healthy volunteers. (B) Both doses of IFN,
1500 IU/ml and 10 000 IU/ml induced the expression ofMxA signiﬁcantly in patients (P
< 0.0001***) as well as in healthy volunteers (P < 0.0001***). (C) In healthy volunteers
imiquimod stimulation led to an up-regulation of MxA compared to the untreated
cells (P < 0.0001***), while it did not affect its expression in patients compared to the
corresponding untreated PBMCs. Results are expressed asmean of relative quantitation
(RQ=2−ΔΔCT) ± standard error of themean (SEM). Stars indicate degree of signiﬁcance.
of IFN stimulation on microRNA expression is not affected by pooling
of PBMCs. Stimulation of PBMCs from individual patients with 1500
IU/ml of IFN induced the expression of miR-146a andmiR-155with a
mean fold increase of 2.6 (P=0.0253*) and2.39 (P=0.0053**), respec-
tively. PBMCs stimulated with 10 000 IU/ml of IFN showed a marked
decrease inmiR-146a andmiR-155expression compared tountreated
cells with a mean fold change of −2.6 (P = 0.017*) and −1.55 (P =
0.0103*), respectively (Fig. 5A and B). These data show that individual
and pooled PBMCs show the same pattern of microRNA expression in
response to IFN stimulation, conﬁrming that pooling of PBMCs does
not interfere with the expression of microRNAs.
MxA expression was measured after stimulation with the two
interferon doses as a positive control, to validate that the used doses
did activate the JAK/STATpathway. Stimulationwith both 1500 IU/ml
and 10 000 IU/ml induced the expression of MxA in patients by 30.95
folds (P < 0.0001***) and 36.5 folds (P < 0.0001***), respectively, as
Fig. 4. Dose–response curves of interferon and imiquimod. (A) Healthy PBMCs were
stimulated with four different IFN doses, 1500 IU/ml, 3000 IU/ml, 6000 IU/ml and 10
000 IU/ml for 6 h, followed by quantiﬁcation of miR-155. 1500 IU/ml of IFN showed
the highest induction of miR-155 (P = 0.0061**).3000 IU/ml and 6000 IU/ml of IFN
did induce miR-155 expression signiﬁcantly. 10 000 IU/ml increased the expression
of miR-155 compared to the untreated cells (P = 0.0061**). (B) Healthy PBMCs were
stimulated with 0.5 μg/ml, 1 μg/ml and 2 μg/ml of imiquimod for 24 h, followed
by quantiﬁcation of miR-155. One microgram per milliliter of imiquimod showed the
highest induction of miR-155 (P < 0.0001***), followed by 0.5 μg/ml (P < 0.0001***)
and 2 μg/ml of imiquimod (P < 0.0001***) compared to the untreated PBMCs. Results
are expressed as mean of relative quantitation (RQ = 2−ΔΔCT) ± standard error of the
mean (SEM). Stars indicate the degree of signiﬁcance.
well as in healthy volunteers by 24.3 folds (P < 0.0001***) and 25.97
folds (P < 0.0001***), respectively (Fig. 3B).
2.6. Dose–response curve of imiquimod
To determine the dose of imiquimod that shows the highest in-
duction of the investigated microRNAs, a dose–response curve was
conducted by stimulating healthy PBMCs with three different im-
iquimod doses, 0.5 μg/ml, 1 μg/ml and 2 μg/ml for 24 h, followed
by quantiﬁcation of miR-155. miR-155 showed a mean fold increase
of 6.77 (P < 0.0001***) following stimulation with 0.5 μg/ml of im-
iquimod. Amean fold increase of 9.82 (P< 0.0001***) was observed in
response to stimulation with 1μg/ml of imiquimod. Twomicrogram
per milliliter of imiquimod increased the expression of miR-155 by
6.57 folds (P < 0.0001***) (Fig. 4B). The highest induction of miR-155
was observed with 1 μg/ml of imiquimod, thus this was the dose
used in the following experiments.
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Fig. 5. Effect of interferon-α2a on the expression of miR-146a and miR-155 in HCV
infected and healthy PBMCs. PBMCs fromhealthy volunteers andHCV infected patients
were cultured in a 24-well plate andwere either left untreated or stimulatedwith 1500
IU/ml or 10 000 IU/ml of IFN-α2a for 6 h. (A) Stimulation of PBMCs with 1500 IU/ml
of IFN led to a signiﬁcant up-regulation of miR-146a in both pooled and individual
PBMCs of patients (P = 0.0357*) and (P = 0.0253*), respectively as well as controls (P <
0.0001***). 10 000 IU/ml of IFN-α2a led to a signiﬁcant down-regulation in pooled and
individual patients (P=0.035*) and (0.017*), but did not affect its expression in controls
compared to the corresponding untreated cells. (B) Stimulation of PBMCs with 1500
IU/ml of IFN induced the expression of miR-155 in both pooled and individual patients
(P = 0.007**) and (P = 0.0053**), respectively, as well as controls (P = 0.0061**). 10
000 IU/ml of IFN suppressed the expression of miR-155 in pooled (P = 0.0266*) and
individual (P = 0.0103*) patients, but induced its expression in controls (P = 0.0061**)
compared to the untreated cells. Results are expressed asmean of relative quantitation
(RQ= 2−ΔΔCT) ± standard error of themean (SEM). Stars indicate degree of signiﬁcance.
2.7. Effect of imiquimod on the expression of miR-146a, miR-155 and
MxA in HCV infected and healthy PBMCs
Expression of miR-146a and miR-155 was measured after stim-
ulation of HCV infected and healthy PBMCs with the TLR-7 agonist,
imiquimod. In healthy controls stimulation with imiquimod signiﬁ-
cantly induced the expression of miR-146a andmiR-155with amean
fold increase of 2.4 (P < 0.0001***) and 4.77 (P = 0.0061**), respec-
tively, compared to the unstimulated PBMCs. However, stimulation
of HCV infected PBMCs with imiquimod suppressed the expression
of miR-146a and miR-155 with a mean fold decrease of −2.61 (P
= 0.0159*) and −2.42 (P = 0.036*), respectively, compared to the
untreated PBMCs (Fig. 6A and B). To exclude any bias that could oc-
cur from pooling of PBMCs the same experiment was repeated using
PBMCs of 6 individual patients, where stimulation with 1 μg/ml of
imiquimod signiﬁcantly suppressed the expression of miR-146a with
a mean fold decrease of −2.00 (P = 0.037*) and miR-155 with a mean
fold change of −2.55 (P = 0.001**) compared to unstimulated PBMCs
(Fig. 6A and B). Relative expression of MxAwas determined following
stimulation of PBMCs with imiquimod as a positive control and to in-
vestigate whether the variation in themicroRNA expression between
patients and healthy controls was also accompanied by a variation
in MxA expression. In healthy volunteers imiquimod stimulation led
to an up-regulation of MxA with a mean fold increase of 12.84 (P <
0.0001***), while it did not affect its expression in patients (Fig. 3C).
Fig. 6. Effect of imiquimod on miR-146a and miR-155 expression in HCV infected and
healthy PBMCs. PBMCs were cultured in a 24-well plate and stimulated with 1μg/ml
imiquimod for 24 h. (A) In healthy PBMCs stimulation with imiquimod induced the
expression of miR-146a signiﬁcantly relative to the untreated controls (P< 0.0001***).
Stimulation of HCV infected PBMCs with imiquimod suppressed the expression of
miR-146a compared to the untreated cells in both pooled (P = 0.0159*) and individual
(P = 0.037*) PBMCs. (B) In healthy PBMCs, stimulation with imiquimod induced the
expression ofmiR-155 compared to the untreated controls (P= 0.0061**).miR-155was
signiﬁcantly down-regulated in response to imiquimod stimulation of both pooled (P
= 0.036*) and individual (P= 0.001**) HCV infected PBMCs. Results are expressed as
mean of relative quantitation (RQ = 2−ΔΔCT) ± standard error of the mean (SEM). Stars
indicate degree of signiﬁcance.
2.8. Correlation analysis between miR-146a and miR-155
Both miR-146a and miR-155 are interferon related microRNAs
with antagonizing actions, despite that they showed very similar ex-
pression behavior in the untreated PBMCs as well as in response to
stimulation with various drugs. This shows that there is a very close
association in the regulation of these microRNAs, making the perfor-
mance of a correlation analysis between the expression of both mi-
croRNAs necessary to conﬁrm this association. Interestingly a strong
positive correlation was observed between miR-146a and miR-155
in non-pooled PBMCs of the individual patients and healthy controls
(Spearman r = 0.8962, P < 0.0001***) and (Spearman r = 0.6930, P =
0.0306*), respectively (Fig. 7 A and B).
3. Discussion
miR-146a and miR-155 are among the epigenetic regulators of
type I IFN-pathway, a representative for host antiviral innate immune
response [7, 8]. Consequently, investigation of the role of these mi-
croRNAs in HCV infection could reveal new ﬁndings that might help
in understanding itsmolecular pathogenesis. This study aimed for the
ﬁrst time at investigating the expression behavior of miR-146a and
miR-155 in the PBMCs of HCV genotype 4 infected patients. PBMCs
were chosen for investigation, because hepatitis C virus is capable of
infecting and replicating within these cells, making them circulating
carriers for the virus [17, 18]. miR-155 has previously shown a posi-
tive correlation between the expression of its precursor gene, BIC, and
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Fig. 7. Correlation analysis between miR-146a and miR-155 in HCV infected and
healthy PBMCs. A positive correlation was observed in the expression pattern of miR-
146a and miR-155 in both (A) healthy controls (Spearman r = 0.6930) (P = 0.0306*)
and (B) HCV infected patients (Spearman r = 0.8962) (P < 0.0001***).
the persistence of HCV RNA in serum and PBMCs of non-genotype 4
infected patients after end of therapy [19]. In addition, miR-155 and
BIC showed a positive correlation with HCV replication in PBMCs of
HCV infected patients [20]. We were concerned with studying the
expression of miR-146a and miR-155 in PBMCs of patients chroni-
cally infected with HCV genotype 4 compared to healthy controls.
No signiﬁcant difference in the relative expression of miR-146a and
miR-155was observed between pooled PBMCs of the two groups (Fig.
2A and B). That was further conﬁrmed by examining the expression
pattern of both microRNAs in PBMCs of individual patients and con-
trols, where expression of the two microRNAs was similar in both
groups (Fig. 2A and B), which demonstrates that pooling of PBMCs
does not affect the expression pattern of these microRNAs. The ex-
pression of miR-146a and miR-155 showed no correlation, neither
with the patients’ clinical and histopathological parameters (Table 2),
nor with the response of the patients to therapy. Contrary to our re-
sults, VSV infectedmurinemacrophages showed an induction ofmiR-
146a and miR-155 expression via a RIG-I dependent pathway [7, 8].
On one hand, a reason for this difference could be that the studies con-
ducted by Hou and colleagues used murine macrophages rather than
human PBMCs for their investigation [7, 8]. On the other hand, these
ﬁndings could be due to the fact that HCV is capable of evading host
immune response by using its NS3/4A protease to cleave the adaptor
protein interferon β promoter stimulator 1 (IPS-1) [21], which is re-
cruited upon activation of RIG-I [22], hence preventing the activation
of this pathway, the induction of miR-146a or miR-155 as well as in-
terferon release. To assess the integrity of the interferon pathway in
HCV infected PBMCs, we measured the expression of MxA, which is a
sensitivemarker for anyminute amounts of interferon [23].We found
adown-regulation inMxAexpression inpatients compared tohealthy
controls (Fig. 3A), which might indicate a functional inhibition in the
pathway that might hinder the induction of miR-146a and miR-155.
It was interesting to locate whether the site of functional attenua-
tion of interferon pathway is upstream or downstream of IFN release.
Therefore, the expression of miR-146a and miR-155 was examined
following stimulation of HCV infected and healthy PBMCs with IFN-
α2a. After performing adose–response experiment onhealthyPBMCs
we chose two doses of IFN, 1500 IU/ml and 10 000 IU/ml that showed
the highest induction ofmiR-155 (Fig. 4A). The stimulationswere per-
formed on pooled PBMCs and PBMCs of individual patients to validate
that the observed changes in microRNA expression in response to in-
terferon is not affected by pooling of PBMCs. Stimulation with 1500
IU/ml of IFN-α2a led to a signiﬁcant up-regulation of miR-146a and
miR-155 in PBMCs of controls and both pooled and individual pa-
tients, however the induction was more pronounced in patients (Fig.
5A and B). That is in concordance with the results obtained in other
studies, where stimulation of healthy PBMCs and pDCswith type I IFN
induced the expressionofmiR-146a andmiR-155, respectively [9, 10].
An interesting phenomenon was observed, where PBMCs stimulated
with a higher IFN-α2a dose (10 000 IU/ml), showed a signiﬁcant
down-regulation of miR-146a and miR-155 in infected pooled and
individual PBMCs compared to the untreated cells (Fig. 5A and B).
To examine whether this biphasic effect in microRNA expression is
also accompanied by the same biphasic response in MxA expression,
we investigated the expression of MxA after stimulation with 1500
IU/ml and 10 000 IU/ml of IFN. Unlike the case with microRNAs, both
doses increased the expression of MxA to almost the same levels (Fig.
3B). Our data suggest that the defect in the interferon pathway is not
downstream of interferon release, i.e. not in the JAK/STAT pathway.
Therefore, we aimed at checking for defects in TLR-7 signaling, as
a representative for signaling pathways upstream of interferon re-
lease and JAK/STAT pathway activation. Accordingly, the expression
of miR-146a and miR-155 was examined following stimulation of
PBMCs of patients and controls with a synthetic TLR-7 agonist, im-
iquimod, for 24 h. To determine the most effective imiquimod dose,
a dose–response experiment was performed and showed that 1 μg/
ml showed the highest induction of miR-155 in healthy PBMCs com-
pared to 0.5 μg/ml and 2 μg/ml (Fig. 4B). miR-146a and miR-155
expression was suppressed in response to stimulation with 1 μg/ml
of imiquimod in pooled and individual HCV infected PBMCs; while in
healthy PBMCs both microRNAs were up-regulated (Fig. 6A and B).
The results observed in healthy PBMCs for miR-146a and miR-155
are consistent with previously reported ﬁndings showing that stim-
ulation of PBMCs or pDCs with imiquimod led to an up-regulation of
bothmicroRNAs [9, 10]. The suppression of bothmicroRNAs observed
in HCV infected PBMCs imply that HCV infection might be interfering
in one way or another with the pathways inducing the expression
of these microRNAs and that this interference is upstream of inter-
feron release and the JAK/STAT pathway, more speciﬁcally in TLR-7
signaling. For further conﬁrmation and to exclude that the inhibitory
effect imposed on microRNA expression in response to imiquimod is
a mimic of the higher IFN dose, the expression of MxA was investi-
gated following stimulation of PBMCs with imiquimod. Contrary to
stimulation with 10 000 IU/ml of IFN, imiquimod did not induce the
expression of MxA in HCV infected PBMCs (Fig. 3C). This strengthens
the suggestion that HCV infection does interfere with TLR-7 signaling
and hence represses activation of the IFN cascade and subsequently
the expression of miR-146a and miR-155, while stimulation with IFN
bypasses this interference and induces bothmicroRNAs. Despite their
paradoxical impact on IFN pathway, a very interesting observation
found in our study was the strong positive correlation in expression
behavior of miR-146a and miR-155 (Fig. 7A and B).
In conclusion, miR-146a and miR-155 are two interferon-related
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microRNAs that are stimulated by TLR-7 and interferon signaling
pathways. Expression of miR-146a and miR-155 did not differ be-
tweenHCV infected andhealthy PBMCs, even thoughbothmicroRNAs
showed an up-regulation in response to other viral infections, such as
VSV, EBV and HSV-1. This might imply that HCV infection represses
the induction of these twomicroRNAs. By tracking the repression site,
we suggest that it lies in TLR-7 signaling pathway andhence upstream
of interferon release, rather than in the JAK/STAT pathway.
4. Patients and methods
4.1. Study subjects
A total of 20 untreated patients chronically infected with HCV
genotype 4 were included in this study. The mean age is 40 years
with a range between 20 and 59. HCV infection was diagnosed in
all patients by the presence of anti-HCV antibodies and HCV RNA in
the serum. All patients had a liver biopsy performed and the histo-
logical ﬁndings were classiﬁed according to Metavir scoring system.
All patients were negative for hepatitis B surface antigen. Patients
were diagnosed and followed up after treatment with weekly injec-
tions of pegIFN-α2a and daily oral doses of ribavirin at Al Kasr Al
Ainy School of Medicine, Cairo University. A total of 10 healthy vol-
unteers with a mean age of 40 years and a range between 23 and 56
were included in this study. Healthy volunteers were blood donors
that were all negative for HCV, HBV and HIV infection. All patients
and healthy volunteers gave their written informed consent. All ex-
periments were performed in compliance with the guidelines of the
institutional review board (IRB) of Al Kasr Al Ainy School of Medicine
in Cairo University and in accordance with the ethical standards of
the declaration of Helsinki.
4.2. Sample handling
Four milliliter of peripheral venous blood were collected in the
presence of an anticoagulant (EDTA) from healthy controls and pa-
tients for isolation of PBMCs. In addition, 3 ml blood samples were
collected from the patients for serum separation for determination
of viral genotype. The blood samples were taken before starting in-
terferon treatment. All samples were processed on the same day and
within few hours after collection.
4.3. Isolation of peripheral blood mononuclear cells
PBMCs were isolated using Ficoll density gradient centrifugation
method. Brieﬂy, peripheral bloodwasdiluted in equal volumeofwash
mix (RPMI 94%, FBS 5%, penicillin/streptomycin 1%). Diluted blood (2
ml) was carefully layered on 3 ml Ficoll reagent, followed by 30 min
centrifugation at 1000 rpm. The buffy layer containing the PBMCs
was collected and washed three times with wash mix. PBMCs were
suspended in 1 ml freeze mix (wash mix, FBS 30%, DMSO 10%) and
immediately frozen at −80 ◦C until use. An average of 8 million cells
were isolated from each patient.
4.4. Serum separation and genotyping
Serum was separated by centrifugation of the blood samples and
was collected and frozen at −80 ◦C until use. Serum was used for de-
termination of the viral genotype. Genotyping was performed at the
National Cancer Institute, using VERSANT
®
HCV Genotype 2.0 Assay
(LiPa, Siemens Healthcare Diagnostics, USA) according to the man-
ufacturer’s instructions. Brieﬂy, the 5′-UTR of the virus is ampliﬁed
with biotinylated primers. Biotin-labeled PCR products are reverse
hybridized to speciﬁc probes attached to nitrocellulose strips and
then incubated with a chromogen. Results are developed in a purple
precipitate that forms a line on the strip. TheHCV genotype is inferred
based on the patterns of hybridizing bands, using the line probe assay
interpretation chart [24].
4.5. Cell culture and stimulation
Two different pools were prepared from the HCV infected PBMCs
of the 20 patients and a third pool was prepared from the PBMCs of
the 10 healthy controls by suspending the cells of the untreated HCV
infected patients or those of healthy controls in culture medium (89%
RPMI supplemented with l-glutamine, 1% penicillin/streptomycin,
10% FBS). PBMCs from each pool as well as non-pooled PBMCs from
6 individual patients were cultured overnight in a 24-well plate at
a concentration of 1 × 106 cells/ml/well. PBMCs were either left
untreated, stimulated with 1500 IU/ml, 3000 IU/ml, 6000 IU/ml or
10 000 IU/ml of interferon α2a (Reiferon, Minapharm, Egypt) for 6
h or stimulated with 0.5 μg/ml, 1 μg/ml or 2 μg/ml of imiquimod
R837 (Enzo Life Sciences, Germany) for 24 h. All experiments were
done in duplicates.
4.6. RNA processing
MicroRNAs and messenger RNAs (mRNAs) were extracted from
PBMCs using mirVanaTM miRNA Isolation Kit (Ambion, USA) accord-
ing to themanufacturer’s instructions.miR-146a andmiR-155 aswell
as the housekeeping gene RNU6B were reverse transcribed into sin-
gle stranded complimentary DNA (cDNA) using TaqMan microRNA
reverse transcription kit (Applied Biosystems, USA). mRNAs were re-
verse transcribed using the high-capacity cDNA reverse transcription
kit (Qiagen, Germany) following manufacturer’s instructions.
4.7. Real time-polymerase chain reaction (PCR)
The relative expression of miR-146a andmiR-155were quantiﬁed
using real time-quantitativepolymerase chain reaction (ABI 7000, Ap-
plied Biosystems, Singapore) using TaqManmicroRNA assay (Applied
Biosystems, USA). The amount of miR-146a and miR-155 was calcu-
lated relative to the amount of the housekeeping gene RNU6B present
in the same sample. The mRNA expression level of the studied gene,
MxA, was quantiﬁed using TaqMan gene expression assays (Applied
Biosystems, USA). The amount of MxA expression was calculated rel-
ative to the amount of mRNA expression of the housekeeping gene
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in the same
sample. Reactions were run in duplicates.
4.8. Statistical analysis
Gene expression is expressed in relative quantitation (RQ =
2−ΔΔCT). Results were expressed as mean ± standard error of the
mean (SEM). Data were analyzed using Prism 5 software, version 5.00
(GraphPad Software, SanDiego, CA).Mann—-WhitneyU testwas used
to draw comparisons between groups. Spearman test was used for
correlation studies. P values less than 0.05 were considered statisti-
cally signiﬁcant.
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